Efstathios T Pavlidis, Theodoros E Pavlidis

Specialty type: Surgery
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Cai ZL, China; Mijwil MM, Iraq
Received: July 26, 2022
Peer-review started: July 26, 2022
First decision: September 5, 2022
Revised: September 5, 2022
Accepted: October 11, 2022
Article in press: October 11, 2022
Published online: October 24, 2022

Abstract
The incidence of cutaneous melanoma appears to be increasing worldwide and this is attributed to solar radiation exposure. Early diagnosis is a challenging task. Any clinically suspected lesion must be assessed by complete diagnostic excision biopsy (margins 1-2 mm); however, there are other biopsy techniques that are less commonly used. Melanomas are characterized by Breslow thickness as thin (< 1 mm), intermediate (1-4 mm) and thick (> 4 mm). This thickness determines their biological behavior, therapy, prognosis and survival. If the biopsy is positive, a wide local excision (margins 1-2 cm) is finally performed. However, metastasis to regional lymph nodes is the most accurate prognostic determinant. Therefore, sentinel lymph node biopsy (SLNB) for diagnosed melanoma plays a pivotal role in the management strategy. Complete lymph node clearance has undoubted advantages and is recommended in all cases of positive SLN biopsy. A PET-CT (positron emission tomography-computed tomography) scan is necessary for staging and follow-up after treatment. Novel targeted therapies and immunotherapies have shown improved outcomes in advanced cases.

Key Words: Surgical oncology; Malignant melanoma; Skin cancer; Cutaneous melanoma; Sentinel lymph node biopsy; Complete lymph node dissection

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: The value of excision biopsy for the initial diagnosis of melanoma in every suspected cutaneous lesion is important. In positive cases, the roles of sentinel node biopsy and subsequent complete lymph node dissection, along with adequate margin excision of the primary lesion site are evaluated to improve the prognosis. Novel biological agents and molecular factors will open new horizons for future management policy.

Citation: Pavlidis ET, Pavlidis TE. Diagnostic biopsy of cutaneous melanoma, sentinel lymph node biopsy and indications for lymphadenectomy. World J Clin Oncol 2022; 13(10): 861-865
URL: https://www.wjgnet.com/2218-4333/full/v13/i10/861.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i10.861

TO THE EDITOR

We read with great interest the recent paper by Koumaki et al.[1] and we would like to congratulate the authors for their excellent trial on melanoma and atypical mole syndrome, which impressed us. This study is meticulous and arduous work that describes, for the first time, many details about the demographic and clinical characteristics of 121 patients. We absolutely agree with the authors that photoprotection education is required to prevent skin cancer development. Taking this opportunity, this paper presents some thoughts and observations from a surgical point of view on the latest developments in biopsy for the diagnosis of suspected primary lesions and the role of sentinel lymph node biopsy and the subsequent prophylactic or therapeutic lymphadenectomy.

The incidence of cutaneous melanoma has steadily increased over the past years. It has been estimated that this increase in the United States has reached up to 3% per year. However, most cases with early-stage disease (I and II) usually have a favorable prognosis[2]. The eighth edition of the American Joint Committee on Cancer (AJCC) staging system is the most widely used standard for the staging and classification of melanoma[2-4]. Cutaneous lesions with macroscopic features that raise the suspicion of melanoma can be used as an alternative for changes in color, outline, bleeding, rapid increase in size, nodular growth and ulceration.

Biopsy and histological examination will initially confirm the diagnosis and determine the stage of the disease, the extent of surgical resection and the management of the sentinel lymph node (SLN). The types of biopsy might be excisional, incisional, shave biopsy (superficial or deep scallop) or punch biopsies[5]. The most preferred excisional biopsy is reliable for defining the T stage in TNM staging. It resects the lesion beyond its margins to an extent of 1-3 mm according to NCCN (National Comprehensive Cancer Network) guidelines or 1-2 mm according to AJCC guidelines. This limit is crucial, given that avoiding lymphatic destruction ensures feasible detection of sentinel lymph nodes[6-5]. The other types of biopsy can potentially lead to misdiagnosis and inaccurate staging. The incisional biopsy removes a small part of the lesion for cosmetic reasons. It is indicated for large lesions of more than 2 cm in diameter that are mainly located on the face.

In a positive biopsy of the initial evaluation of the suspected skin lesion, sentinel lymph node biopsy (SLNB) follows. This is because the involvement of regional lymph nodes is considered an important prognostic factor for survival. SLNB is indicated by the current data and 15% to 20% of patients have regional node metastasis[9]. In addition, the presence or absence of nodal micrometastases is the most important prognostic factor in early-stage melanoma, particularly in intermediate thickness melanoma [10]. Thus, SLNB is considered the standard of care and has high diagnostic value. It is a minimally invasive procedure with a low complication rate[9,11]. The detection of sentinel lymph nodes is performed either 24 h preoperatively by Tc-99 administration and the use of a gamma probe or intraoperatively by methylene blue administration. Moreover, their combination can be used. A positive SLNB results in a complete lymph node dissection (CLND). This process provides adequate regional disease control and has an indication for adjuvant chemotherapy[11]. A negative SLNB has a minimal likelihood of metastasis. The final CLND biopsy ensures accurate staging and prognosis. Furthermore, CT (computed tomography) and PET (positron emission tomography) scans contribute to staging by defining the M (distant metastasis)[12]. However, the prognosis is influenced by disease progression [13].

The incidence of nodal metastases clearly depends on the thickness of the primary melanoma. Lesions more than 1 mm in thickness are more likely to have metastases in the sentinel node, and lesions between 1 mm and 2 mm only have metastases in the sentinel node. However, lesions more than 2 mm in thickness have metastases in additional lymph nodes and distant metastases[9]. According to the excision biopsy, when the depth of invasion (Breslow thickness) is less than 1 mm, or from others, less than 0.75 mm, then the positive SLNB will be less than 5%. An exception to this rule is the mitotic index (≥ 1 mitoses/mm²), especially in cases with a Breslow thickness between 0.75 mm and 0.99 mm. The rate of false-negative SLNB reached 1.5% to 4.1%[11].
In the case of early-stage (pT1b, pT2a) melanoma with sentinel node micrometastases, when the deposits are less than 0.3 mm in maximum diameter, no adjuvant treatment will be necessary. Otherwise, when they are equal to or more than 0.3 mm, adjuvant systemic therapy could be beneficial [14].

The final differential diagnosis between melanoma and dysplastic nevus is made by histopathology. A molecular assay would be of value for early-stage lesions, but thus far, there is no such test[15]. PET-CT has the greatest diagnostic accuracy both for staging and follow-up. However, for the latter, the currently used immunotherapy can create various organ side effects; thus, radiologists should be aware of this[12].

The dataset of dermoscopic images is a useful tool for the early detection of skin cancer[16]. Ultrasound-guided fine needle aspiration cytology (FNAC) and core needle biopsy (CNB) can be used for the detection of subcutaneous or lymph node metastases[17]. Melanomas can be diagnosed in early stages (50%). They are more commonly located on the extremities in women and on the back in men. On the lower limbs, they can be more invasive and are without sex differences[18].

Current recommendations indicate complete excision biopsy to avoid residual disease in the complementary resection after partial excision biopsy. However, this treatment does not influence survival[19]. A recent large, retrospective study found that SLNB was more likely to be indicated for a Breslow depth >1 mm or mitotic rate ≥ 1/mm². It was less likely to be indicated in patients of older age (> 75-years-old) and those without an extremity location[20].

The prognostic value of complete lymph node dissection (CLND) after positive SNDB is observation and therapeutic lymph node dissection (TLND) has been evaluated[21], despite the initial aspect of a nonsignificant difference between them[22]. A large, retrospective study from Italy including 2086 patients after CLND for lymph node involvement found improved survival. The 3-year survival was 79%, the 5-year survival was 70%, and the 10-year survival was 54%[23]. The preliminary results indicated that the clinicopathologic information (thickness, mitoses, age, and Breslow thickness 2 mm) and gene expression profiling (CP-GEP) were independent predictive factors for lymphatic metastases [24]. Similarly, 31-gene expression profiling (i31-GEP-SLNB) has become commercially available[25]. A vitamin D level < 9.25 ng/mL is another negative independent prognostic factor for survival. It is associated with ulceration formation in melanoma[26].

A stage-based follow-up scheme has recently been proposed by the European consensus for melanoma[27].

Tilmanocept, a CD206 receptor-targeted novel radiotracer, has recently been introduced for lymphoscintigraphy to assess nodal mapping[28].

Adequate margin excision (1-2 cm, depending on the invasion depth) has been the standard therapy, despite the de-escalation of its extent, together with SLNB[10,29]. Targeted therapy and immunotherapy have further improved the prognosis[30].

In conclusion, SLNB is indicated for melanoma stage IB (T1b ≤ 1 mm, ulceration, and mitoses >1 mm²) and stage II. In positive cases, CLND is required instead of TLND. SLNB offers staging accuracy and has indications for adjuvant therapy. Thus, it can improve prognosis and survival. New diagnostic modalities and immunotherapies will contribute further to improved outcomes.

FOOTNOTES

Author contributions: Pavlidis TE designed the research, analyzed the data and revised the letter; Pavlidis ET performed research, analyzed data and wrote the letter.

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Greece

ORCID number: Efstatios T Pavlidis 0000-0002-7282-8101; Theodoros E Pavlidis 0000-0002-8141-1412.

S-Editor: Chen YL
L-Editor: Filipodia
P-Editor: Chen YL
REFERENCES

1. Kounaki D, Papadakis M, Kouloumvakou S, Krasagakis K. Awareness, knowledge, and attitudes towards sun protection among patients with melanoma and atypical mole syndrome. World J Clin Oncol 2022; 13 (7): 587-598. [PMID: 36157160 DOI: 10.5306/wjco.v13.i7.587]

2. Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther 2018; 18: 775-784. [PMID: 29923435 DOI: 10.1080/14737140.2018.1492926]

3. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017; 67: 93-99 [PMID: 28094848 DOI: 10.3322/caac.21388]

4. Hynes MC, Nguyen P, Groome PA, Asai Y, Mavor ME, Baetz TD, Hanna TP. A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma. BMC Cancer 2022; 22: 720 [PMID: 35778691 DOI: 10.1186/s12885-022-09781-0]

5. Hickl TJ, Hernandez-Isirrizry R, Boll JM, Jones Coleman JE. Accuracy of diagnostic biopsy for cutaneous melanoma: implications for surgical oncologists. Int J Surg Oncol 2013; 2013: 196493 [PMID: 24102023 DOI: 10.1155/2013/196493]

6. Doherty SM, Jackman LM, Kirwan JF, Dunne D, O’Connor KG, Rouse JM. Comparing initial diagnostic excision biopsy of cutaneous malignant melanoma in primary versus secondary care: A study of Irish National data. Eur J Gen Pract 2016; 22: 267-273 [PMID: 27848254 DOI: 10.1080/13814788.2016.1252386]

7. Murchie P, Raja EA, Lee AJ, Campbell NC. Mortality and morbidity after initial diagnostic excision biopsy of cutaneous melanoma in primary versus secondary care. Br J Gen Pract 2013; 63: e563-e572 [PMID: 23972197 DOI: 10.3399/bjgp13X670697]

8. McKenna DB, Lee RJ, Prescott RJ, Doherty VR. The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival. Br J Dermatol 2002; 147: 48-54 [PMID: 12100184 DOI: 10.1046/j.1365-2133.2002.04181.x]

9. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cormier JN, Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH, American Society of Clinical Oncology; Society of Surgical Oncology. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012; 30: 2912-2918 [PMID: 22778321 DOI: 10.1200/JCO.2011.40.3519]

10. Han D, Thomas DC, Zager JS, Pockaj B, White RL, Leong SP. Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. World J Clin Oncol 2016; 7: 174-188 [PMID: 27081640 DOI: 10.5306/wjco.v7.i2.174]

11. Morton DL, Hoon DS, Cochrane AJ, Turner RR, Essner R, Takeuchi H, Wanek LA, Glass E, Foshag LJ, Hsueh EC, Bilchik AJ, Elashoff D, Elashoff R. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal micrometastasis and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003; 238: 538-49; discussion 549 [PMID: 14530725 DOI: 10.1097/01.sla.0000068564.45557.cb]

12. Granata V, Simonetti I, Fusco R, Setola SV, Izzo F, Scarpatto L, Vanella V, Festicino L, Simeone E, Ascierto PA, Petrelli A. Management of cutaneous melanoma: radiologists challenging and risk assessment. Radiol Med 2022; 127: 899-911 [PMID: 35854109 DOI: 10.1007/s11547-022-01522-4]

13. Bujic A, Rugge M, De Luca G, Zorzi M, Cozzolino C, Vecchietti A, Del Fiore P, Tropea S, Bortolami A, Benini P, Rossi CR, Mocellin S. Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective. Melanoma Res 2022; 32: 353-359 [PMID: 35855661 DOI: 10.1097/CMR.0000000000000841]

14. Moncrieff MD, Lo SN, Scolley RA, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Hess EM, Hsuem EC, Bilchik AJ, Elashoff D, Elashoff R. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal micrometastases. Ann Surg Oncol 2022; 29: 473-476 [PMID: 35763046 DOI: 10.1245/s10434-022-09078-3]

15. Xavier-Junior JCC, Ocana-West JR. Dysplastic melanocytic nevi: Are molecular findings the key to the diagnosis? Ann Diagn Pathol 2022; 60: 152006 [PMID: 35839551 DOI: 10.1016/j.anndiagpath.2022.152006]

16. Frazier M, Faouri E. On the Automatic Detection and Classification of Skin Cancer Using Deep Transfer Learning. Sensors (Basel) 2022; 22 [PMID: 35808463 DOI: 10.3390/s22149493]

17. Salim DN, Obinah MPB, Ternov NK, McCullagh MJ, Larsen MS, Hendel HW, Hölmich LR, Chakera AH. Fine needle and core needle ultrasound guided biopsies for assessing suspected melanoma metastasis in lymph nodes and subcutaneous tissue. J Surg Oncol 2022 [PMID: 35792684 DOI: 10.1002/jso.26998]

18. Tsai MC, Hodgson K, Sandila N, Bosworth A, Hull PR. An Examination of Melanoma Detection and Characteristics at a Nova Scotia Tertiary Care Centre, From 2015-2019. J Cutan Med Surg 2022; 26: 473-476 [PMID: 35763046 DOI: 10.1177/120347542211080978]

19. Ramiscal JAB, Stern SL, Wilson AK, Lorimer PD, Lee NA, Guldofar MB, Foshag LJ, Fischer TD. Does Residual Invasive Disease in Wide Local Excision after Diagnosis with Partial Biopsy Technique Influence Survival in Melanoma? J Am Coll Surg 2022; 235: 49-59 [PMID: 35703962 DOI: 10.1016/j.jamcollsurg.2022.05.013]

20. Ollek S, Minkova S, Taqi K, Chen L, Martinka M, Davis N, Hamilton T, Stuart H. Population-based assessment of sentinel lymph node biopsy in the management of cutaneous melanoma. Can J Surg 2022; 65: E394-E403 [PMID: 35701006 DOI: 10.1503/cjs.019320]

21. Morton DL, Thompson JF, Cochrane AJ, Mozillo N, Nieweg OE, Rossos DF, Hsueh EC, Bilchik AJ, Elashoff D, Elashoff R. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal micrometastases. Ann Surg Oncol 2022; 29: 473-476 [PMID: 35763046 DOI: 10.1245/s10434-022-09078-3]
22 Rutkowski P, Nowecki ZI, Zurawski Z, Dzwierski W, Nasierowska-Guttmejer A, Switaj T, Ruka W. In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection. *Eur J Cancer* 2006; 42: 159-164 [PMID: 16324835 DOI: 10.1016/j.ejca.2005.10.012]

23 Tropea S, Del Fiore P, Maurichi A, Patuzzo R, Santinami M, Ribero S, Quaglino P, Caliendo V, Borgognoni L, Sestini S, Giudice G, Nacciero E, Caracò C, Cordova A, Solari N, Piazzalunga D, Tauceri F, Carcoforo P, Lombardo M, Cavallari S, Mocellin S, Italian Melanoma Intergroup (IMI). The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086). *BMC Cancer* 2022; 22: 610 [PMID: 3569273 DOI: 10.1186/s12885-022-09705-y]

24 Sadurni MB, Meves A. Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies. *Mod Pathol* 2022 [PMID: 35654998 DOI: 10.1038/s41379-022-01101-y]

25 Marchetti MA, Dusza SW, Bartlett EK. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma. *JAMA Dermatol* 2022; 158: 680-683 [PMID: 35475908 DOI: 10.1001/jamadermatol.2022.0970]

26 Moro R, Sánchez-Silva A, Aguerralde-Martin M, González-Cuevas R, Peruiil-Bagolini L, Traves V, Manrique-Silva E, Requena C, Nagore E. Prognostic Value of Vitamin D Serum Levels in Cutaneous Melanoma. *Actas Dermosifiliogr* 2022; 113: 347-353 [PMID: 35623724 DOI: 10.1016/j.ad.2021.11.001]

27 Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JH, Hölter C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lobbé C, Lytvynenko B, Malvéhy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part I: Diagnostics: Update 2022. *Eur J Cancer* 2022; 170: 236-255 [PMID: 35570085 DOI: 10.1016/j.ejca.2022.03.008]

28 Mwagiru D, Shivashankar P, Wong E, Farlow D, Cambden B, Abdul-Razak M. Tilmanocept as a novel tracer for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer. *ANZ J Surg* 2022 [PMID: 35848587 DOI: 10.1111/ans.17868]

29 Santamaria-Barria JA, Mannen JMV. Surgical Management of Melanoma: Advances and Updates. *Curr Oncol Rep* 2022 [PMID: 35657482 DOI: 10.1007/s11912-022-01289-x]

30 Rathod D, Kroumpouzos G, Lallas A, Rao B, Murrell DF, Apalla Z, Grabbe S, Loquai C, Goldust M. Critical Review of the Sentinel Lymph Node Surgery in Malignant Melanoma. *J Drugs Dermatol* 2022; 21: 510-516 [PMID: 35533034 DOI: 10.36840/JDD.6198]
